Latest Vaccination Stories

BLUE BELL, Pa., March 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the fourth quarter and year ended December 31, 2012. Total revenue was $1.1 million and $4.1 million for the quarter and year ended December 31, 2012, compared to $1.6 million and $9.8 million for the same periods in 2011. Total operating expenses for the quarter and year and ended December 31, 2012, were $7.4 million and $27.6 million as compared to $7.4...

--Study published in Journal of Virology demonstrates GEN-003 capable of eliciting immune responses that provide protection against recurrent disease in preclinical models-- CAMBRIDGE, Mass., March 18, 2013 /PRNewswire/ -- Genocea Biosciences Inc., a clinical-stage company pioneering novel T cell vaccines, announced today the publication of new data to support GEN-003, its investigational vaccine for the treatment of HSV-2. The results, which are available today in the print edition...

Lawrence LeBlond for redOrbit.com - Your Universe Online Concerns about safety and side effects of receiving the human papillomavirus (HPV) vaccine have left many parents guarded about offering the option to their teenage daughters, even with increased recommendations by health experts. Paul Darden, MD, of the University of Oklahoma Health Sciences Center, and colleagues have found that more than 40 percent of parents reported in 2010 that they did not plan to vaccinate their teen...

Initial vaccinations for human papillomavirus (HPV) at a young age is important for maximizing quadrivalent HPV vaccine effectiveness according to a Swedish study published March 13 in the Journal of the National Cancer Institute. HPV vaccination programs have been launched around the world in hopes of preventing cervical cancer and other HPV-related cancers. While incidence of genital warts is the earliest possible disease outcome to measure the efficacy of the HPV vaccine, the results of...

- Unblinded Phase III Preliminary Results Demonstrate Vaccine Efficacy Rate of 95.4% BEIJING, March 14, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, announced today preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD"). The primary objective of the study was to...

The widespread introduction of a chicken pox vaccine in Australia in 2006 has prevented thousands of children from being hospitalized with severe chicken pox and saved lives, according to new research. In a national study of chicken pox admissions at four participating Australian children's hospitals, researchers found the number of children hospitalized with chicken pox or shingles had dropped by 68% since 2006. The research was led by Associate Professor Helen Marshall from the...

SEATTLE, March 13, 2013 /PRNewswire/ -- TapImmune Inc. ("TapImmune" or the "Company") (OTCQB: TPIV), an immunotherapy company focused on the development of novel peptide and gene-based vaccine technologies, announced today that the Company will present at the Florida Road Show Conference in Boca Raton, Florida on Thursday, March 14, 2013. This conference, hosted by Corporate Roadshow and Undiscovered Equities, will feature presentations by CEOs and CFOs of promising emerging growth...

BLUE BELL, Pa., March 12, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it has closed an underwritten offering of 27,377,266 shares of its common stock and warrants to purchase up to 13,688,633 shares of common stock at a combined price of $0.55 per share and related warrant for gross proceeds of $15.1 million. The warrants are exercisable at an exercise price of $.7936 per share and will expire, unless exercised, on the date that is 180 days...

CAMBRIDGE, Mass., March 12, 2013 /PRNewswire/ -- Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has added Katrine Bosley, a proven biotechnology industry leader, as an independent director. "Katrine brings a unique and important perspective to our board as we continue to advance our lead programs within this new class of vaccines," said Chip Clark, CEO of Genocea. "The breadth of her experience in creating strategic and...

redOrbit Staff & Wire Reports - Your Universe Online A contagious form of cancer has brought the Tasmanian devil to the edge of extinction, but new hope for the carnivorous marsupial could soon be on the way in the form of a vaccine. It was less than two decades ago that scientists first discovered the ailment known as devil facial tumor disease (DFTD), which spreads from one mammal to another when they bite each other on the face during a fight, researchers from the University of...